Patients aged 18 years with a confirmed diagnosis of type 2 diabetes mellitus (T2DM) receiving GLP-1RA treatment
Transferrin-SPIONs (Tf-SPIONs) bind transferrin receptors (TfR), while lactoferrin-SPIONs (Lf-SPIONs) engage lactoferrin receptors (LRP1), facilitating receptor-mediated endocytosis into tumor cells
Beneficiaries need to meet at least one of the following, based on their BMI and health history when they first started GLP-1 therapy: A BMI of 35 or higher A BMI of 30 or higher, with a history of heart failure, uncontrolled hypertension, or chronic kidney disease A BMI of 27 or higher, with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease Beneficiaries who already have GLP-1 coverage under Part D for a separate condition, such as type 2 diabetes or sleep apnea, arent eligible for the Bridge
Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth during repeated needle punctures for multi-dose vials
Taking supplements at the right time improves their effectiveness
LpIA1-dependent utilization of host lipoyl peptides enables Listeria cytosolic growth and virulence